Repligen (RGEN) Q4 2025: Analytics Grows 37%, Multi-Year Upgrade Cycle Accelerates Margin Upside

2026-02-24 | By EarningsIQ Research

Repligen capped 2025 with standout analytics growth and broad-based margin expansion, outpacing bioprocessing peers and setting a prudent but opportunity-rich 2026 outlook. Strength in proteins, chromatography, and analytics—each posting double-digit gains—offset muted downstream equipment demand, while management’s focus on innovation, M&A, and cross-sell is shaping a more resilient, diversified business model. Operating leverage, a robust funnel, and a multi-year product upgrade cycle anchor the path to further growth, even as macro and regulatory uncertainties temper near-term guidance.

Summary

• Analytics Upgrade Cycle Extends Growth Runway: Early-stage Solo VPE Plus adoption signals multi-year revenue durability.
• Margin Expansion Anchored by Portfolio Diversification: High-growth franchises and disciplined OpEx underpin operating leverage.
• 2026 Guidance Balances Cautious Macro with High-Probability Funnel: Robust pipeline and new product launches set up optionality for upside.

Performance Analysis

Repligen delivered a strong Q4, with revenue growth outpacing the broader bioprocessing market and margin expansion exceeding prior guidance. The quarter saw organic growth of 14% and full-year growth of 16% on a reported and non-COVID basis, reflecting broad-based execution across product lines. Standout performance came from the analytics franchise, which grew 37% for the year, and proteins, up 31%. Chromatography also delivered over 25% growth, while filtration saw high single-digit gains.

Geographically, Europe led regional growth with over 20% YoY gains, while North America and Asia Pacific posted mid- to high-teens increases. China returned to growth after a period of contraction, supported by strong Q4 orders. Gross margin expanded 220 basis points for the year, driven by volume leverage and price, offsetting inflation and minor tariff impacts. Operating margin improvements were most pronounced when excluding the dilutive effects of recent M&A.

• Analytics Franchise Outperformance: 37% annual growth, with a multi-year Solo VPE Plus upgrade cycle just beginning, supporting >20% growth guidance for 2026.
• Portfolio Breadth Drives Resilience: Proteins, chromatography, and analytics counterbalance flat capital equipment and muted downstream demand.
• Margin Expansion from Volume and Price: 240 bps organic margin expansion YoY, with disciplined OpEx and selective investment in scalable infrastructure.

Capital equipment remained flat YoY, reflecting industry-wide CapEx caution, but consumables and services provided a buffer. The company’s ability to outperform in a mixed-demand environment demonstrates the value of its diversified model and cross-selling momentum.

Executive Commentary

Strategic Positioning

1. Analytics as a Growth Engine

Repligen’s analytics business, driven by the Solo VPE Plus platform, is in the early stages of a multi-year upgrade cycle, with less than 100 of 1,500–2,000 installed units upgraded to date. This provides a durable, recurring revenue stream and cross-sell opportunities, especially as the analytics portfolio broadens through M&A and internal innovation.

2. Portfolio Diversification and Cross-Sell

Management’s focus on key account penetration—selling 2.5 times as many product lines to large pharma and CDMO customers versus 2019—has increased wallet share and reduced dependence on any single segment. The commercial team is incentivized to cross-sell, and services are being built out as a higher-margin, recurring business line.

3. Disciplined Capital Allocation and M&A

M&A remains the top capital allocation priority, with a focus on differentiated technologies that address customer pain points and deliver accretive returns. The 908 Devices acquisition and Novasign partnership reflect a strategy of augmenting the portfolio with analytics and digital capabilities, while maintaining a strong balance sheet for further deals.

4. Margin Expansion and Fit-for-Growth Investments

Operating leverage was achieved through disciplined OpEx management and targeted investment in IT, AI, and leadership, laying a scalable foundation for future growth. Margin expansion is expected to continue in 2026, even as the company invests in commercial and product lifecycle capabilities.

5. Innovation Pipeline and New Modalities

New product launches in proteins, filtration (Proconnex Mix One), and analytics (Solo VPE Plus, Flow VPX) are expected to drive incremental growth. The company is also developing mid-IR technology and integrating advanced analytics (Raman, Maverick) into existing platforms, targeting both new modalities and established drug markets.

Key Considerations

Repligen’s 2025 execution highlights the benefits of a diversified, innovation-driven bioprocessing model, but the 2026 guidance reflects a prudent approach given macro and regulatory uncertainties. Investors should weigh the following:

Key Considerations:

• Upgrade Cycle Durability: Early innings of the Solo VPE Plus cycle support multi-year analytics growth, with a large installed base yet to be converted.
• Cross-Sell and Service Attachment: Key account penetration and higher analytics service attachment rates are expanding recurring revenue and margin.
• China and Emerging Markets: Return to growth after a reset, with incremental investment and local partnerships aiming to outpace company-wide growth rates.
• Capital Equipment and Downstream Demand: Flat outlook persists, but any improvement in CapEx spending or macro normalization could provide upside surprise.

Risks

Macro uncertainty, including delayed CapEx decisions by large pharma and slow FDA approvals for new modalities, could dampen near-term growth. Tariff volatility and policy shifts remain minor but persistent headwinds. M&A integration risk is present, particularly as the company pursues further deals. Management’s guidance prudently accounts for these variables, but execution risk remains if market normalization lags or innovation cycles slow.

Forward Outlook

For Q1 2026, Repligen guided to:

• Low single-digit sequential revenue decline from Q4, reflecting normal seasonality but strong YoY positioning.
• Modest sequential gross margin expansion, with more pronounced gains expected later in the year.

For full-year 2026, management guided:

• $810–840 million in revenue (9–13% organic growth), with analytics expected to grow >20%, and filtration, proteins, and chromatography all in the low double digits.
• Gross margin expansion of 125 bps at midpoint, and adjusted EPS of $1.93–$2.01 (up 15% at midpoint).

Management highlighted several factors that could influence guidance:

• Conversion of a record-high, high-probability funnel into orders and revenue.
• Potential upside from macro normalization, increased FDA approvals, or improved CapEx spending by pharma.

Takeaways

Repligen’s 2025 execution validates its diversified, innovation-led model, with analytics and proteins providing multi-year growth levers and margin expansion.

• Multi-Year Analytics Cycle: Early-stage Solo VPE Plus upgrades and a broadened analytics portfolio anchor durable double-digit growth prospects.
• Margin and Operating Leverage: 240 bps organic margin expansion in 2025, with further gains expected as OpEx discipline and scalable investments bear fruit.
• Watch for Macro and CapEx Inflection: Any acceleration in pharma CapEx or regulatory tailwinds would provide upside to a prudently set 2026 guide.

Conclusion

Repligen enters 2026 with strong momentum, a robust innovation pipeline, and disciplined margin expansion, but remains mindful of macro and regulatory uncertainties. The company’s multi-year upgrade cycles and cross-sell strategy provide a resilient foundation for continued outperformance, with upside optionality if the bioprocessing market normalizes faster than expected.

Industry Read-Through

Repligen’s results highlight the value of portfolio breadth and recurring analytics revenue in the bioprocessing tools sector, especially as capital equipment markets remain uneven. The early innings of a multi-year analytics upgrade cycle suggest that companies with installed base leverage and service attachment can outperform through macro cycles. Margin expansion through operating leverage and disciplined investment is increasingly critical as inflation and tariff pressures persist. The muted downstream demand and cautious CapEx spending echo broader industry trends, while the return to growth in China and emerging markets signals incremental opportunities for global players.

RGEN Health Care Bioprocessing Analytics Margin Expansion Innovation Cross-Sell Upgrade Cycle